Reformulary Group’s prescription drug tool receives TELUS Outstanding Product Award

World News: . []

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Last night at the 33 annual Canadian Advanced Technology Alliance Leadership Awards Gala, Reformulary Group received the TELUS Outstanding Product Achievement Award for ™, a consumer tool that gives Canadians access to independent and expert research on prescription drugs.

DrugFinder was built as an educational tool to address gaps in prescription drug coverage. There are many Canadians who cannot afford to pay for their medication because they lack prescription drug coverage altogether or have inadequate coverage and cannot cover the cost of their medication. With DrugFinder, patients can search prescription drugs to see if what they’ve been prescribed is preferred by the expert panel – meaning that the drug provides the best combination of clinical and cost-effectiveness. DrugFinder also gives Canadians access to recommended – or preferred – alternatives for drugs that are considered non-preferred.

“With DrugFinder, we want to empower Canadians to take control of their health,” said Helen Stevenson, founder and CEO of Reformulary Group. “We are incredibly proud of this recognition and will continue to help educate patients and empower them to make smart drug choices and take control of their health.” 

The TELUS Outstanding Product Award recognizes a Canadian organization for a technology engineering development or solution that has resulted in a world-class M-Health product and has enhanced Canada’s international reputation for healthcare innovation and excellence. In the shift from physician-focused, disease oriented and hospital-based care to consumer-driven wellness, DrugFinder puts power in the hands of the patient.

Recently, Reformulary Group trained Alexa to enhance the DrugFinder user experience. By asking questions into an Alexa-enabled device like the Amazon Echo, Alexa will respond to the patient’s inquiries. Users can ask questions such as, “Are there better options for Drug X?” Or, “What is the generic of Drug X?”

More news and information about Reformulary Group

Published By:

Globe Newswire: 18:22 GMT Wednesday 16th May 2018

Published: .

Search for other references to "reformulary" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers